Table 1 Patient characteristics in the training and validate sets.
From: A proposed prognostic 7-day survival formula for patients with terminal cancer
| Â | Training (n = 374) | Validation (n = 353) | P-value |
|---|---|---|---|
Age (years) | 67 (54, 75) | 67 (58, 75) | 0.318 |
Gender | Â | Â | 0.428 |
   Male | 228 (61.0%) | 205 (58.1%) |  |
   Female | 146 (39.0%) | 148 (41.9%) |  |
Diabetes mellitus | 92 (24.6%) | 120 (34.2%) | 0.005* |
Hypertension | 151 (40.4%) | 148 (41.9%) | 0.671 |
Diagnosis | Â | Â | Â |
   Lung cancer | 77 (20.6%) | 58 (16.4%) | 0.150 |
   Liver cancer | 74 (19.8%) | 71 (20.1%) | 0.912 |
   Colon cancer | 44 (11.8%) | 42 (11.9%) | 0.956 |
   Stomach cancer | 18 (4.8%) | 25 (7.1%) | 0.195 |
   Head Neck cancer | 41 (11.0%) | 58 (16.4%) | 0.032* |
   Pancreas cancer | 16 (4.3%) | 14 (4.0%) | 0.833 |
   Male GU cancer | 16 (4.3%) | 11 (3.1%) | 0.408 |
   Female GU cancer | 27 (7.2%) | 22 (6.2%) | 0.596 |
   Breast cancer | 16 (4.3%) | 9 (2.5%) | 0.201 |
   Esophagus cancer | 11 (2.9%) | 12 (3.4%) | 0.833 |
   Unknown and others | 46 (12.3%) | 50 (14.2%) | 0.458 |
Treatment | Â | Â | Â |
   Operation | 154 (41.2%) | 165 (46.9%) | 0.122 |
   Chemotherapy | 191 (51.1%) | 190 (53.8%) | 0.457 |
   Radiotherapy | 116 (31.0%) | 143 (40.5%) | 0.008* |
Laboratory Parameters | Â | Â | Â |
   WBC (*1000/cumm) | 10.01 (7.05, 15.19) | 10.41 (7.34, 14.93)†| 0.824 |
   Hemoglobin (g/dl) | 10.3 (9.1, 11.7) | 10.6 (8.9, 11.9)†| 0.340 |
   Platelet (*1000/cumm) | 210 (128, 312) | 222 (138, 331)†| 0.309 |
   Glucose (mg/dl) | 117 (99, 147) | 118 (97, 156)†| 0.941 |
   BUN (mg/dl) | 21 (15, 32) | 19 (12, 32)†| 0.067 |
   Creatinine (mg/dl) | 0.9 (0.7, 1.4) | 0.7 (0.5, 1.1)†| <0.001* |
   SGOT (IU/L) | 34 (20, 70) | 35 (22, 81)†| 0.335 |
   SGPT (IU/L) | 23 (14, 46) | 26 (15, 47)†| 0.382 |
   Albumin (g/dl) | 3.1 (2.7, 3.4) | 2.8 (2.4, 3.2)†| <0.001* |